Xenotransplantation is a promising strategy to address the shortage of organs for human transplantation. Concerns about pig-to-human immunological compatibility and the risk of cross-species transmission of porcine endogenous retroviruses (PERVs) have impeded the clinical application of this approach.
Using CRISPR-Cas9, we inactivated all the PERVs in a porcine primary cell line and generated PERV-inactivated pigs via somatic cell nuclear transfer. Our study highlights the value of PERV inactivation to prevent cross-species viral transmission and demonstrates the successful production of PERV-inactivated animals to address safety concerns in clinical xenotransplantation. Using our genome editing platform, we are creating pigs with advanced immunological modifications to address immunological and functional compatibility issues.
Free and open to the public. Registration is closed, but walk-in attendees will be accommodated if space is available.